JLABS seeks lung cancer solutions in Shanghai
Why JLABS Shanghai Head Sharon Chan sees lung cancer as a priority
As Johnson & Johnson gears up to launch its Shanghai JLABS site early next year, the incubator’s head, Sharon Chan, has pegged lung cancer as one of the first priorities.
Chan sees opportunity in China in multiple fields, as the country builds capabilities in artificial intelligence and big data. The prevalence of lung cancer means J&J can compete in an indication where it’s been late to the party in the U.S.
J&J has no marketed therapies in lung cancer, and has a Phase II program on the FGFR inhibitor erdafitinib, and a Phase I program on JNJ-61186372, a bispecific antibody against EGFR and c-MET.
On Nov. 5, J&J’s Janssen Pharmaceuticals Inc. unit announced a deal with South Korean biotech Yuhan Corp. to license the Phase I/II non-small cell lung cancer (NSCLC) therapy lazertinib. Janssen will receive exclusive rights to develop and commercialize lazertinib worldwide, except in South Korea, and is responsible for